West Lafayette, IN, United States of America

Philip Stewart Low

This inventor holds 111 USPTO granted patents and 83 published patent applications, plus 8 CIPO patents and 29 EPO patents, primarily in Targeted Drug Delivery (CPC class A61K49-0052). Top assignees: Purdue Research Foundation, Endocyte, Inc., Seattle Children's Hospital. Active years: 1992-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip Stewart Low. Retrieved from https://idiyas.com/inventor/philip-stewart-low

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 111 (Patent Applications = 83)

% Patents Active = 92.8

CIPO Patents = 8 (Patent Applications = 23)

EPO Patents = 29 (Patent Applications = 66)

Average Co-Inventor Count = 2.6

ph-index = 21

Forward Citations = 1,659(Granted Patents)

Forward Citations (Not Self Cited) = 1,129(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Glenview, IL (US) (2012)
West Lafayetter, IN (US) (2014)
West Lafayette, IN (US) (1992 - 2024)

Company Filing History:

105 out of 2,781

Purdue Research Foundation

Seattle Children's Hospital

patents

4. 3 out of 1,685

University of Utah Research Foundation

patents

5. 2 out of 16

On Target Laboratories, LLC

patents

6. 2 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

where one patent can have more than one assignee

Years Active: 1992-2026

Loading Chart...

Areas of Expertise:

Targeted Drug Delivery

CAR-T Cell Therapy

Imaging Agents

Lipid-Conjugates

Tumor Imaging

PSMA Ligands

Fibroblast Activation Protein

Bone Fracture Repair

Cholecystokinin B Receptor

Nanoparticle Mapping

Erythrocyte Band 3 Inhibitors

Folate Receptor Conjugates

111 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721898 - Fibroblast activation protein (FAP)—targeted antifibrotic therapy (2026-09-01),

2. 12622973 - Rejuvenation of CAR T cell (2026-05-12),

3. 12599683 - Mapping nanoparticles (2026-04-14),

4. 12589155 - Efficient synthesis of lipid-fluorescein conjugates for CAR-T cell therapy (2026-03-31),

5. 12576165 - Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors (2026-03-17),

6. 12508319 - Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof (2025-12-30),

7. 12496292 - PSMA binding ligand-linker conjugates and methods for using (2025-12-16),

8. 12485179 - Cholecystokinin B receptor targeting for imaging and therapy (2025-12-02),

9. 12473264 - Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof (2025-11-18),

10. 12397069 - Fibroblast activation protein (FAP)-targeted imaging and therapy (2025-08-26),

11. 12397059 - Compounds and methods for the treatment and prevention of fibrotic disease states and cancer (2025-08-26),

12. 12343403 - Targeted ligand-payload based drug delivery for cell therapy (2025-07-01),

13. 12319721 - Targeting anabolic drugs for accelerated fracture repair (2025-06-03),

14. 12269862 - Methods of use for CAR T cells (2025-04-08),

15. 12240870 - Sequencing method for CAR T cell therapy (2025-03-04),

Title: **The Innovative Journey of Philip Stewart Low**

Introduction

Philip Stewart Low, based in West Lafayette, IN (US), is a distinguished inventor with an impressive portfolio of around 100 patents. Renowned for his work in drug delivery systems, Low's advancements have greatly contributed to the field of cell therapy and fracture repair, showcasing his significant role in the intersection of science and innovation.

Latest Patents

Among his latest groundbreaking patents is a platform titled "Targeted Ligand-Payload Based Drug Delivery for Cell Therapy." This innovative drug delivery system allows for a flexible fine-tuning of cell therapies by using an engineered fusion protein that is coupled with a high-affinity ligand. This ligand carries a payload of drugs that can be internalized by transplanted cells, thus enabling researchers to observe or manage the effects of transplanted cell therapy more effectively.

Another remarkable patent is "Targeting Anabolic Drugs for Accelerated Fracture Repair." This invention pertains to the targeted delivery of growth factors, vasoactive peptides, and other anabolic peptide drugs to bone fractures, facilitating accelerated healing. This targeted approach emphasizes Low's commitment to advancing therapeutic methods to enhance patient outcomes.

Career Highlights

Philip Stewart Low has made notable contributions while working with various esteemed organizations. He has been part of the Purdue Research Foundation, where he likely engaged in significant research and technological development. Additionally, his tenure at Endocyte, Inc. highlights his involvement with a firm focused on developing advanced therapies, particularly in the realm of personalized medicine.

Collaborations

Throughout his innovative career, Low has collaborated with distinguished colleagues such as Sumith A Kularatne and Christopher Paul Leamon. These partnerships have not only contributed to the success of various projects but have also fostered an environment of shared knowledge and breakthrough ideas.

Conclusion

In conclusion, Philip Stewart Low's extensive patent portfolio and collaborative efforts underscore his pivotal role as an inventor in the fields of drug delivery and therapeutic innovation. His work continues to inspire and lead advancements that may significantly improve medical treatments, demonstrating the importance of creativity and technology in enhancing human health.

Profile summary based on public USPTO records.